RT @MeralElRamahiMD: âï¸Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN p
Tweet Content
⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF
Show on Archive Page
On
Display in Search Results
On
PDQ
On